Pharma BD Deal Intelligence
Seattle Genetics / Immunomedics
2017 · Licensing/Option · $2.0B · Pending
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2022 at the earliest for this deal, once/if it closes.
Key facts
- Announced Feb 10, 2017
- Deal value $2.0B
- Deal type Licensing/Option
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2017 deals